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Abstract As a step towards understanding the complex
differences between normal cells and cancer cells, we have used
suppression subtractive hybridization (SSH) to generate a profile
of genes overexpressed in primary colorectal cancer (CRC).
From a 35 000 clone SSH-cDNA repertoire, we have screened
400 random clones by reverse Northern blotting, of which 45
clones were scored as overexpressed in tumor compared to
matched normal mucosa. Sequencing showed 37 different genes
and of these, 16 genes corresponded to known genes in the public
databases. Twelve genes, including Smad5 and Fls353, have
previously been shown to be overexpressed in CRC. A series of
known genes which have not previously been reported to be
overexpressed in cancer were also recovered: Hsc70, PBEF,
ribophorin II and Ese-3B. The remaining 21 genes have as yet no
functional annotation. These results show that SSH in conjunc-
tion with high throughput screening provides a very efficient
means to produce a broad profile of genes differentially
expressed in cancer. Some of the genes identified may provide
novel points of therapeutic intervention.
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1. Introduction
The formation and progression of tumors are associated
with changes in protein expression, which in most cases can
be correlated with abnormal levels of mRNA. The mortality
from colorectal cancer (CRC) has changed very little over the
past 50 years, which emphasizes the need for therapies based
on a greater understanding of the molecular changes that
underlie CRC. The value in the identi¢cation of overexpressed
molecules in CRC is three fold: (i) overexpressed genes may
be used as markers for biological behavior such as invasive-
ness or metastasis, which could be of signi¢cant value for
prognosis and therapeutic management, (ii) di¡erentially ex-
pressed tumor cell surface markers may be targets for anti-
body-based immunotherapy [1], (iii) understanding the pheno-
typic changes associated with the overexpression of cancer
genes allows for the formulation of pathways or targets for
therapeutic intervention.
There is clearly a need for methods that allow for the rapid
identi¢cation of di¡erentially expressed genes associated with
a particular disease state. The ¢rst approach to describe the
identi¢cation of di¡erentially expressed genes was based on
subtractive hybridization. This method was eventually super-
seded by di¡erential display [2]. The development of serial
analysis of gene expression (SAGE) [3,4] and cDNA micro-
array technology [5,6] has allowed for the generation of global
expression pro¢les in cancer. Although both SAGE and
cDNA microarrays have proved powerful tools for the con-
struction of gene indexes, they have a critical limitation in that
both methods are dependent on the availability of previously
cloned genes.
We have used an alternative method called suppression
subtractive hybridization (SSH) [7] because this method is
not dependent on the availability of previously cloned
cDNA sets and will allow for the cloning of informative frag-
ments of unknown gene sequences. SSH allows for the nor-
malization of frequent and rare cDNAs and subtraction of
cDNAs common between two populations. Suppression
PCR allows for the exponential ampli¢cation of di¡erentially
expressed genes and the suppression of sequences present in
equal amounts in both cDNA populations. This technique is
capable of high enrichment factors [7] and is amenable to
microarray analysis. Arrayed SSH repertoires will have the
advantage that redundant spotting will be eliminated and
much smaller and e⁄cient DNA chips can be produced [8].
We have used SSH for the ¢rst time to identify di¡erentially
expressed genes in primary CRC. We have generated a large
repertoire which is highly enriched for overexpressed genes.
From this repertoire, we have isolated many novel gene se-
quences of which epithelial speci¢c Ets transcription factor 3B
(Ese-3B), pre-B cell enhancing factor (PBEF), heat shock cog-
nate 70 (Hsc70), ribophorin II and 21 yet to be functionally
annotated genes are of particular interest.
2. Materials and methods
2.1. Tumor material
Fresh frozen tissue from a primary stage III rectal adenocarcinoma
and matched upstream non-neoplastic mucosa were obtained from a
60 year old Caucasian male following surgical resection. This tissue
was used for cDNA library construction.
2.2. mRNA isolation and cDNA synthesis
Total RNA was isolated from both normal mucosa and tumor
using a RNA extraction kit (QIAGEN). We puri¢ed mRNA using
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oligotex beads (QIAGEN). Using 0.5 Wg mRNA, cDNA synthesis was
performed using the Cap¢nder cDNA synthesis kit according to the
manufacturer’s instructions (Clontech).
2.3. Generation of cDNA library using SSH
SSH was performed between primary colorectal tumor cDNA and
matched normal mucosal cDNA, using the PCR select cDNA sub-
traction kit (Clontech) according to the manufacturer’s recommenda-
tions.
2.4. Cloning of the SSH repertoire into a T/A cloning vector
The SSH-cDNA repertoire was cloned into the T/A cloning vector
pCR2.1 (Invitrogen) and transformed into the Escherichia coli strain
TG1 by electroporation (Bio-Rad) at 2.5 kV, 25 WF and 200 6. The
library was plated on 2UTY agar plates (16 g/l bacto-tryptone, 10 g/l
yeast extract, 5 g/l NaCl, 15 g/l bacto-agar) containing ampicillin at
100 Wg/ml and 2% w/v glucose. After overnight growth at 37‡C, the
repertoire was recovered in 2UTY medium plus ampicillin at 100 Wg/
ml by £ooding the plates and frozen in aliquots in 15% w/v glycerol.
The size of the cDNA library was determined by plating an original
sample on 2UTY plates containing ampicillin, X-gal (40 Wl of a 40
mg/ml stock per 90 cm plate) and IPTG (40 Wl of a 100 mM stock per
90 cm plate).
2.5. Screening using reverse Northern blotting
Individual recombinant clones were inoculated into sterile 96 well
microtiter plates (Costar) containing 100 Wl of 2UTY medium, con-
taining ampicillin at 100 Wg/ml, and were grown overnight at 30‡C,
after which 5 Wl was removed and transferred to PCR 96 well tubes
(Sarstedt). PCR was performed and inserts were ampli¢ed using spe-
ci¢c primers (Invitrogen).
After PCR, 10 Wl samples were loaded onto 1.5% agarose TBE gels
(Hybaid) in duplicate (10 Wl per slot with 80 samples on each gel).
PCR products were denatured in 0.4 M NaOH, 0.6 M NaCl and
blotted onto nylon membranes (Schleicher and Schuell). After trans-
fer, blots were neutralized using 2USSC (0.3 M NaCl, 30 mM sodium
citrate pH 7.0), 0.5 M Tris-HCl pH 7.4. Filters were hybridized as in
[9] and probed with equivalent amounts of 32P-labelled (Boehringer
Mannheim), RsaI-digested double-stranded cDNA, derived from nor-
mal mucosa and CRC cDNA. Both probes were of approximately
equal speci¢c activity (109 dpm/Wg DNA). Filters were washed with
0.5USSC, 1% SDS at room temperature. Duplicate ¢lters were pre-
pared and di¡erential signals between colon tumor cDNA fragments
and normal cDNA fragments identi¢ed after overnight exposure to a
phosphorimaging screen (Bio-Rad). Densitometric scanning of dupli-
cate blots allowed for the calculation of the ratio of signal obtained
with tumor to normal cDNA probes and normal cDNA probes. Pos-
itive clones were sequenced and submitted to the National Centre for
Biotechnology Information for homology search.
2.6. Northern analysis and semi-quantitative reverse transcriptase
(RT-) PCR
Total RNA was prepared and analyzed as in [9]. Probes were gen-
erated by PCR ampli¢cation and labelled using random priming
(Boehringer Mannheim). Unincorporated label was removed prior
to hybridization using Sephadex G50. Filters were then exposed to
a phosphorimaging screen (Bio-Rad).
RNA was normalized for glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) by Northern blotting and ¢rst strand cDNA synthesis
was performed using random primers. As a control for genomic DNA
contamination, all reactions were set up in duplicate with the control
sample lacking reverse transcriptase. Gene speci¢c primers were de-
signed to amplify fragments between 400 and 700 bp during 39 cycles
at an annealing temperature of 55‡C. Primers for c-Myc are coding
strand primer (5P-AAGCTCGTCTCAGAGAAGCT-3P), non-coding
strand primer (5P-AGCCTGCCTCTTTTCCACAG-3P) ; for secreted
protein, acidic and rich in cysteine (SPARC) coding strand primer
(5P-CCATGGAGCATTGCACCACCCGC-3P), non-coding strand
primer is (5P-CAGATCCGTGTCCACCCATGTGCC-3P) ; for inter-
feron inducible protein 1-8D (IFN 1-8D) coding stand primer is (5P-
GCCATTGTAGAAAAGCGTGTGAGG-3P), non-coding strand pri-
mer is (5P-CGCCTACTCCGTGAAGTCTAGGG-3P); for PBEF cod-
ing strand primer is (5P-GTGCCTGTATCTGTGGTCAG-3P), non-
coding strand primer is (5P-CACACACCCAGTCATAAAGCC-3P).
Ten Wl aliquots were removed from the PCR reaction at 20, 24, 28,
32 and 36 cycles and ran on a 1.5% TBE agarose gel. Band intensities
were compared between matched samples of tumor and normal mu-
cosa, GAPDH expression was included as an internal control to nor-
malize the di¡erential signal ratio between normal and tumor samples.
2.7. In situ hybridization
To test expression using in situ hybridization, SPARC was cloned
into pCR2.1 in two orientations. Antisense and sense RNA probes
were generated by T7 RNA polymerase using digoxigenin (DIG)-la-
belled UTP (Roche Diagnostics). Five Wm tissue sections of both neo-
plastic and normal colon were hybridized with 100 ng/ml antisense
DIG-RNA and sense DIG-RNA as a negative control. After incuba-
tion with anti-DIG antibodies labelled with alkaline-phosphatase, the
probes were visualized with 4-nitroblue tetrazolium chloride and 5-
bromo-4-chloro-3-indolyl-phosphate as in [10].
3. Results
3.1. Identi¢cation of genes overexpressed in colon cancer using
SSH
As previous results using SSH have concentrated on using
cell lines [11], we decided to apply SSH to a single matched
tumor normal tissue pair. Inserts from 400 random clones
from a 35 000 independent clone SSH repertoire were ampli-
¢ed by PCR and then separated on a gel for subsequent re-
verse Northern analysis. This gave clear hybridization signals
and genes di¡erentially expressed between normal mucosa and
tumor could be easily detected (Fig. 1). The di¡erential signal
obtained by reverse Northern blotting was quantitated using a
phosphorimager and the average increase in signal in tumor
compared to normal was approximately six for genes de-
scribed in both Table 1 and Table 2. Of the 400 clones ana-
lyzed, 45 were detected as overexpressed in tumor compared
to normal and 63 genes gave a positive hybridization signal
but did not show overexpression in tumor material. The re-
maining 292 genes gave no hybridization signal. Of these, we
expect approximately 41% to be di¡erentially expressed but
lying outside the sensitivity limit of the reverse Northern anal-
ysis. These probably represent the ‘rarest’ transcripts. The
total number of genes analyzed that showed a di¡erential
signal was 11%. This is in close agreement with that previ-
ously reported by Von Stein et al. (1997) [11], who reported
that 12.5% of genes recovered by SSH showed a di¡erential
signal using a similar screening assay.
Fig. 1. An example of a reverse Northern blot. Example of part of
a reverse Northern blot probed with complex cDNA probes pre-
pared from primary tumor tissue and normal mucosa. Bands a and
b represent genes overexpressed in the tumor, c represents a gene
showing equal abundance in both normal and tumor tissue, d repre-
sents background binding and thus remains undetected by reverse
Northern screening.
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Of the 45 genes identi¢ed as overexpressed, 37 represented
di¡erent transcripts and of these, 16 showed homology to
known genes in the public databases. Furthermore, 12 genes
have previously been shown to be overexpressed in cancer:
CEA [12], NCA [13], c-Myc [14], SPARC [15], ¢bronectin
precursor [16], cytochrome c-oxidase subunit I, ATPase-6
[17], lactate dehydrogenase B (LDH-B), [18], IFN 1-8D [4]
Caldesmon [19], Smad5 [20] and Fls353 (GenBank submission
March 1999, accession number AB024704) (Table 1). The
remaining 21 genes showed no signi¢cant homology with
any functionally annotated sequences in the public databases
(Table 2). It is interesting to note that our SSH repertoire had
a surprisingly low level of redundancy in that of the 45 genes
identi¢ed, only ¢ve genes (CEA, NCA, Smad5, cytochrome c-
oxidase subunit I and ATPase-6) were recovered more than
once.
The average fragment insert size corresponding to the
known genes was 723 bp, which is substantially larger than
the 256 bp that can be statistically predicted by the 4 bp
restriction enzyme used to generate the cDNA fragments for
SSH. This has been reported previously and is due to the
suppression PCR e¡ect being more e⁄cient for shorter mole-
cules of less than 200 nucleotides [7]. This preferential enrich-
ment of longer molecules is balanced by the tendency of the
subtraction procedure to favor shorter cDNA fragments
which are more e⁄ciently hybridized, ampli¢ed and cloned
than longer fragments.
3.2. Con¢rmation of overexpression of selected genes by a
second independent method
For further target validation, we have used semi-quantita-
tive RT-PCR, Northern analysis and in situ hybridization. We
have con¢rmed overexpression of c-Myc, SPARC and PBEF
in three matched tumor normal samples by semi-quantitative
RT-PCR (Fig. 2) of which PBEF has not previously been
reported as overexpressed in CRC. Further con¢rmation of
overexpression of SPARC was provided by in situ hybridiza-
tion and preferential staining of the vessel wall in tumor tissue
compared to matched normal mucosa can be seen (Fig. 3).
Using Northern analysis, we have con¢rmed IFN 1-8D and
Table 1
List of overexpressed genes in primary CRC with homology to known sequences in the public databases
Identity Homologya Ratio T/Nb Appearancec Accession no.d
Col-p1 Cytochrome c-oxidase 1 6 2 J01415
Col-p2 CEA 7.5 3 M17303
Col-p3 NCA 7.8 4 M18728
Col-p4 SPARC 2.4 1 M25746
Col-p7 c-Myc 7 1 J00120
Col-p11 Ribophorin II 4.5 1 NM002951
Col-p13 Fibronectin precursor 10 1 K00799
Col-p15 Ese-3B 5.6 1 AF124439
Col-p16 Hsc70 7.9 1 Y00371
Col-p19 Smad5 3.4 2 U59913
Col-p29 ATPase subunit-6 9 2 J01415
Col-p35 Caldesmon 3PUTR 7.25 1 X93334
Col-p37 PBEF 6 1 U02020
Col-p38 LDH-B 10.5 1 Y00711
Col-p42 IFN 1-8D 6 1 X57351
Col-p49 Fls353 3.0 1 AB024704
aGene with functional annotation with which maximum homology is obtained using a BLAST search of the public databases.
bThe increase in signal obtained with the complex tumor cDNA probe compared to the complex normal cDNA probe as obtained by reverse
Northern analysis and quantitated using densitometric scanning.
cThe number of times that the known gene appears in the analysis of 400 clones.
dThe accession number in the public databases.
Fig. 2. Semi-quantitative RT-PCR of selected overexpressed genes.
The ¢gure shows semi-quantitative RT-PCR for matched tumor and
normal mucosa samples. Samples were normalized using the house-
keeping gene GAPDH which did not show a di¡erential signal be-
tween tumor and normal tissue. Analysis was performed on the
known genes SPARC, IFN 1-8D, c-Myc and PBEF. Matched tissue
samples used to construct the SSH library are indicated with an as-
terisk.
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LDH-B in n = 3/4 and n = 4/4 matched tumor and normal
samples, respectively (Fig. 4).
4. Discussion
We have generated for the ¢rst time a large collection of
di¡erentially expressed genes in primary CRC by reverse
Northern screening of a SSH-derived cDNA library. We de-
cided to generate a pro¢le of di¡erentially expressed genes in
primary tumor tissue rather than in tumor cell lines, believing
that this will give a more physiologically relevant output of
abnormally regulated genes. Although cell lines are an ex-
tremely useful and consistent source of tumor material, a cau-
tionary note has most recently been provided by the SAGE
method. Only 26% of the genes identi¢ed as overexpressed in
Table 2
Overexpressed genes in primary CRC with no functional annotation
Identity Ratio T/Na Accession no.b
Col-p8 6 AA455483
Col-p9 4.8 AA449997
Col-p12 5.4 No homology
Col-p14 5.3 U75653
Col-p17 5.3 AA535206
Col-p18 5.7 AA635946
Col-p20 15.6 AA252109
Col-p22 3.5 AA782573
Col-p23 4.2 AA236320
Col-p24 9.6 No homology
Col-p25 10.8 AA313600
Col-p26 5.4 N33897
Col-p27c 17 D87666
Col-p28 2.6 N44337
Col-p30 4.6 AI142134
Col-p39 3.8 AA336609
Col-p40 5.6 AI188015
Col-p43 6.3 AA314633
Col-p44 5.3 W07312
Col-p45 5 AA040810
Col-p50 14 AA029988
aQuantitated increase in signal obtained with the tumor complex
cDNA probe compared to the complex normal cDNA probe in re-
verse Northern analysis.
bThe accession number in the public databases.
cCol-p27 has homology to a Hsp90-related protein. All gene frag-
ments shown were recovered once in the reverse Northern screening
analysis.
Fig. 3. Detection of SPARC expression by in situ hybridization. A: Colorectal tumor tissue probed with a labelled SPARC antisense RNA.
B: Normal mucosa probed with labelled SPARC antisense RNA. C: Colorectal tumor tissue probed with labelled SPARC sense RNA.
D: Normal mucosa probed with labelled SPARC sense RNA.
Fig. 4. Northern analysis of selected overexpressed genes. Northern
analysis of matched primary tumor and normal total RNA samples.
Total RNA samples were normalized for GAPDH prior to loading.
LDH-B gave a band of the expected size (1.4 kb) and showed over-
expression in tumor compared to normal in four matched samples.
IFN 1-8D which is only a partial gene sequence in the public data-
base gave a band of 2.7 kb in Northern blotting and showed over-
expression in tumor compared to normal in three out of four
matched samples. The tumor normal sample pair used to construct
the SSH library is shown by an asterisk.
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colon cancer cell lines were also shown to be overexpressed in
primary tumor tissue [4]. Most of the known genes we have
recovered have not been reported by the SAGE method with
only four genes being common to both our SSH analysis and
SAGE (i.e. ¢bronectin precursor, SPARC, LDH-B and IFN
1-8D). However, the vast majority of known genes we have
recovered by SSH have previously been correlated with cancer
using other techniques. This suggests that although there is
overlap in the pro¢le of genes overexpressed, there may be
di¡erent biases associated with each technique.
The SSH procedure is ideally suited for the identi¢cation of
oncogenes. One of the new genes we have recovered is Col-
p15, which has recently been described as Ese-3B (accession
number AF124439). Ese-3B is a new member of the Ets tran-
scription factor family which includes several oncogenes that
induce tumorigenesis when overexpressed. The Ese-3B protein
is most closely related to the recently identi¢ed ESX (epithe-
lial restricted with serine box) oncoprotein which has been
reported to be stimulated in the early stages of breast cancer
and to be activated by the HER2/neu breast cancer oncogene
[21]. Also the identi¢cation of PBEF as an overexpressed gene
in CRC is a novel ¢nding. PBEF has been reported as cyto-
kine which is believed to act on early B-lineage precursor cells
[22] and is normally expressed in bone marrow stromal cells
or activated human lymphocytes. The same sequence has also
been reported as a putative lymphocyte Go/G1 switch gene
(i.e. G0S9) [23]. Finally, there is an increasing body of evi-
dence relating defects in Smad genes to carcinogenesis and as
such, the recovery of Smad5 as a di¡erentially expressed gene
product is an important ¢nding. The Smad5 gene belongs to a
family of genes that transduce signals from the TGF L family
of cytokines. Defects in this pathway are thought to result in
non-responsiveness to TGF L. The 612 bp RsaI fragment of
the Smad5 gene that we isolated (Col-p19) did not show any
mutations as has been reported for Smad2 and Smad4 [24,25].
A recent immunohistochemical study has reported that recep-
tor-activated Smad genes, like Smad5, show increased expres-
sion in a fraction of tumor cells compared to epithelial mu-
cosa of normal colon [20].
Cell surface or secreted molecules are ideal targets for im-
munotherapy. One such target is SPARC, which is a 43 kDa
glycoprotein that interacts with the extracellular matrix and is
believed to co-ordinate both endothelial cell proliferation and
migration in processes such as wound healing and angiogen-
esis. The level of expression of SPARC has previously been
shown to correlate with the progression of colon cancer [15].
Two of the overexpressed genes we have isolated belong to the
heat shock family of proteins, Hsc70 and a Hsp90 homologue
(Col-p27)(Table 2). Heat shock proteins have been shown to
have di¡erential expression in gastrointestinal tumors [26] and
there is some evidence that members of this family of proteins
are present on the surface of tumor cells [27,28].
In addition to the known genes, we have a substantial list of
genes which have as yet no functional annotation and in the
majority of cases only have homology to EST sequences in the
public databases. We intend to validate these targets by im-
munohistochemistry using the rapid generation of antibody
probes to EST-derived peptides using phage display technol-
ogy [29].
Due to the heterogeneity of tumors, it would be interesting
to produce a SSH-cDNA repertoire from pooled tumor and
pooled normal samples which will allow for biasing generi-
cally overexpressed cancer genes. However, our data suggest
that sampling of only one tumor sample yields exclusively
‘generic’ markers. This in part could be due to the reverse
Northern screening method in that the sensitivity threshold
identi¢ed only the genes with the strongest di¡erential signal.
The rarest transcripts, which may be related to tumor hetero-
geneity, are not detected. In our analysis, the rare transcripts
are probably represented by the 292 clones screened that did
not give a hybridization signal. Furthermore, we can extrap-
olate that at least 41% of these will be di¡erentially expressed
but currently lying outside the sensitivity limit of the reverse
Northern analysis.
To increase the throughput capacity of SSH, it is possible
to combine this technology with microarray analysis. A po-
tential advantage of such an approach is that redundant spot-
ting of highly expressed non-di¡erentially expressed genes is
avoided allowing for smaller DNA chips to be produced for
high throughput analysis. A recent publication by Yang et al.
(1999) [8] has indeed reported the marriage of SSH and
cDNA microarray technology for the rapid identi¢cation of
di¡erentially expressed genes.
We show that SSH in conjunction with an e⁄cient screen-
ing procedure is an extremely valuable method to produce a
broad pro¢le of cloned di¡erentially expressed genes. Through
application of this technique for the ¢rst time to primary CRC
tumor tissue, we report the isolation of several novel genes of
which the di¡erential expression is likely to be physiologically
relevant.
References
[1] Scott, A.M. and Welt, S. (1997) Curr. Opin. Immunol. 9, 717^
722.
[2] Liang, P. and Pardee, A.B. (1992) Science 257, 967^971.
[3] Velculescu, V.E., Zhang, L., Vogelstein, B. and Kinzler, K.W.
(1995) Science 270, 484^487.
[4] Zhang, L., Zhou, W., Velculescu, V.E., Kern, S.E., Hruban,
R.H., Hamilton, S.R., Vogelstein, B. and Kinzler, K.W. (1997)
Science 276, 1268^1272.
[5] DeRisi, J., Penland, L., Brown, P.O., Bittner, M.L., Meltzer,
P.S., Ray, M., Chen, Y., Su, Y.A. and Trent, J.M. (1996) Nat.
Genet. 14, 457^460.
[6] Schena, M., Shalon, D., Davis, R.W. and Brown, P.O. (1995)
Science 270, 467^470.
[7] Diatchenko, L., Chris Lau, Y.-F., Campbell, A.P., Chenchik, A.,
Moqadam, F., Huang, B., Lukyanov, S., Lukyanov, K., Gur-
skaya, N., Sverdlov, E.D. and Siebert, P.D. (1996) Proc. Natl.
Acad. Sci. USA 93, 6025^6030.
[8] Yang, G.P., Ross, D.T., Kuang, W.W., Brown, P.O. and Weigel,
R.J. (1999) Nucleic Acids Res. 27, 1517^1523.
[9] Korn, S.H., Wouters, E.F., Wesseling, G., Arends, J.W. and
Thunnissen, F.B. (1997) Am. J. Respir. Crit. Care Med. 155,
1117^1122.
[10] De Block, M. and Debrouwer, D. (1993) Anal. Biochem. 215,
86^89.
[11] Von Stein, O.D., Thies, W.G. and Hofmann, M. (1997) Nucleic
Acids Res. 25, 2598^2602.
[12] Ahnen, D.J., Kinoshita, K., Nakane, P.K. and Brown, W.R.
(1987) Gastroenterology 93, 1330^1338.
[13] Berry, R.D. and Paraskeva, C. (1988) Carcinogenesis 9, 447^450.
[14] Sugio, K., Kurata, S., Sasaki, M., Soejima, J. and Sasazuki, T.
(1988) Cancer Res. 48, 4855^4861.
[15] Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S.,
Basset, P., Chambon, P. and Gespach, C. (1995) Int. J. Cancer
64, 70^75.
[16] Christensen, L., Nielsen, M., Andersen, J. and Clemmensen, I.
(1988) Cancer Res. 48, 6227^6233.
FEBS 23009 2-12-99
S.E. Hufton et al./FEBS Letters 463 (1999) 77^82 81
[17] Torroni, A., Stepien, G., Hodge, J.A. and Wallace, D.C. (1990)
J. Biol. Chem. 265, 20589^20593.
[18] Rutzky, L.P. and Siciliano, M.J. (1982) J. Natl. Cancer Inst. 68,
81^90.
[19] Porter, R.M., Holme, T.C., Newman, E.L., Hopwood, D., Wil-
kinson, J.M. and Cuschieri, A. (1993) J. Pathol. 170, 435^440.
[20] Korchynskyi, O., Landstrom, M., Stoika, R., Funa, K., Heldin,
C.H., ten Dijke, P. and Souchelnytskyi, S. (1999) Int. J. Cancer
82, 197^202.
[21] Chang, C.H., Scott, G.K., Kuo, W.L., Xiong, X., Suzdaltseva,
Y., Park, J.W., Sayre, P., Erny, K., Collins, C., Gray, J.W. and
Benz, C.C. (1997) Oncogene 14, 1617^1622.
[22] Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S. and McNiece,
I. (1994) Mol. Cell Biol. 14, 1431^1437.
[23] Siderovski, D.P., Blum, S., Forsdyke, R.E. and Forsdyke, D.R.
(1990) DNA Cell Biol. 9, 579^587.
[24] Gemma, A., Hagiwara, K., Vincent, F., Ke, Y., Hancock, A.R.,
Nagashima, M., Bennett, W.P. and Harris, C.C. (1998) Oncogene
16, 951^956.
[25] Riggins, G.J., Kinzler, K.W., Vogelstein, B. and Thiagalingam,
S. (1997) Cancer Res. 57, 2578^2580.
[26] Ehrenfried, J.A., Herron, B.E., Townsend Jr., C.M. and Evers,
B.M. (1995) Surg. Oncol. 4, 197^203.
[27] Multho¡, G., Botzler, C., Jennen, L., Schmidt, J., Ellwart, J. and
Issels, R. (1997) J. Immunol. 158, 4341^4350.
[28] Takashima, S., Sato, N., Kishi, A., Tamura, Y., Hirai, I., Tor-
igoe, T., Yagihashi, A., Takahashi, S., Sagae, S., Kudo, R. and
Kikuchi, K. (1996) J Immunol. 157, 3391^3395.
[29] Hoogenboom, H.R., de Bruine, A.P., Hufton, S.E., Hoet, R.M.,
Arends, J.W. and Roovers, R.C. (1998) Immunotechnology 4, 1^
20.
FEBS 23009 2-12-99
S.E. Hufton et al./FEBS Letters 463 (1999) 77^8282
